Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Sunitinib 19Everolimus 17Bevacizumab 13aldesleukin 11Sorafenib 11Interleukin-2 10Cyclophosphamide 10Axitinib 10Nivolumab 9fludarabine phosphate 7fludarabine 7pembrolizumab 5Gemcitabine 5temsirolimus 4pazopanib 4Ipilimumab 4peginterferon alfa-2b 3durvalumab 3cabozantinib 3Radiosurgery 3Interferon-alpha 3Granulocyte-Macrophage Colony-Stimulating Factor 3Filgrastim 3Erlotinib Hydrochloride 3Cryosurgery 3vandetanib 2spartalizumab 2perflutren 2ixabepilone 2chiron 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Kidney Neoplasms × Technetium Tc 99m Sestamibi × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡